Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BETAHISTINE DIHYDROCHLORIDE

All products: not a benefit

Auro-Betahistine · DIN 02449145 · 8mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Betahistine · DIN 02449145 Manufacturer: Auro Pharma Inc.; listing date 2016-02-25 Health Canada: Marketed since 2015-11-30 · brand AURO-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Betahistine: Formulary list price $0.2070/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2070 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93496 · Verify on the e-Formulary ↗ (DIN 02449145)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02449145). DIN 02449145: Auro-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id AUR Source form: Tab; strength: 8mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.2070; ministry $0.2070 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449145 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93496
Interchangeable products
M-Betahistine · DIN 02519682 · $0.2259 Mint-Betahistine · DIN 02538121 · $0.2259 NRA-Betahistine · DIN 02544911 · $0.2259 Serc · DIN 02240601 · not recorded Teva-Betahistine · DIN 02280183 · $0.2259
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449145
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Betahistine · DIN 02519682 · 8mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Betahistine · DIN 02519682 Manufacturer: Mantra Pharma Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-07-27 · brand M-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Betahistine: Formulary list price $0.2259/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2259 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100892 · Verify on the e-Formulary ↗ (DIN 02519682)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02519682). DIN 02519682: M-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id MAT Source form: Tab; strength: 8mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.2259; ministry $0.2259 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519682 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100892
Interchangeable products
Auro-Betahistine · DIN 02449145 · $0.2070 Mint-Betahistine · DIN 02538121 · $0.2259 NRA-Betahistine · DIN 02544911 · $0.2259 Serc · DIN 02240601 · not recorded Teva-Betahistine · DIN 02280183 · $0.2259
Shortage status: resolved shortage (ended 2025-02-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519682
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Betahistine · DIN 02538121 · 8mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Betahistine · DIN 02538121 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-01-31 Health Canada: Marketed since 2023-10-20 · brand MINT-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Betahistine: Formulary list price $0.2259/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2259 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102687 · Verify on the e-Formulary ↗ (DIN 02538121)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02538121). DIN 02538121: Mint-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id MIN Source form: Tab; strength: 8mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.2259; ministry $0.2259 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538121 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102687
Interchangeable products
Auro-Betahistine · DIN 02449145 · $0.2070 M-Betahistine · DIN 02519682 · $0.2259 NRA-Betahistine · DIN 02544911 · $0.2259 Serc · DIN 02240601 · not recorded Teva-Betahistine · DIN 02280183 · $0.2259
Shortage status: resolved shortage (ended 2025-06-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538121
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Betahistine · DIN 02544911 · 8mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Betahistine · DIN 02544911 Manufacturer: Nora Pharma; listing date 2024-08-30 Health Canada: Marketed since 2024-06-05 · brand NRA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Betahistine: Formulary list price $0.2259/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2259 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103354 · Verify on the e-Formulary ↗ (DIN 02544911)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02544911). DIN 02544911: NRA-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id NRA Source form: Tab; strength: 8mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.2259; ministry $0.2259 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544911 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103354
Interchangeable products
Auro-Betahistine · DIN 02449145 · $0.2070 M-Betahistine · DIN 02519682 · $0.2259 Mint-Betahistine · DIN 02538121 · $0.2259 Serc · DIN 02240601 · not recorded Teva-Betahistine · DIN 02280183 · $0.2259
Shortage status: resolved shortage (ended 2025-03-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544911
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Betahistine · DIN 02280183 · 8mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Betahistine · DIN 02280183 Manufacturer: Teva Canada Limited; listing date 2011-05-19 Health Canada: Marketed since 2014-01-09 · brand TEVA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Betahistine: Formulary list price $0.2259/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2259 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76586 · Verify on the e-Formulary ↗ (DIN 02280183)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02280183). DIN 02280183: Teva-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id TEV Source form: Tab; strength: 8mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.2259; ministry $0.2259 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02280183 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76586
Interchangeable products
Auro-Betahistine · DIN 02449145 · $0.2070 M-Betahistine · DIN 02519682 · $0.2259 Mint-Betahistine · DIN 02538121 · $0.2259 NRA-Betahistine · DIN 02544911 · $0.2259 Serc · DIN 02240601 · not recorded
Shortage status: discontinued (2025-08-28, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02280183
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Betahistine · DIN 02449153 · 16mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Betahistine · DIN 02449153 Manufacturer: Auro Pharma Inc.; listing date 2016-02-25 Health Canada: Marketed since 2015-11-30 · brand AURO-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Betahistine: Formulary list price $0.3557/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3557 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93497 · Verify on the e-Formulary ↗ (DIN 02449153)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02449153). DIN 02449153: Auro-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id AUR Source form: Tab; strength: 16mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.3557; ministry $0.3557 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449153 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93497
Interchangeable products
Betahistine · DIN 02466449 · $0.3557 Co Betahistine · DIN 02374757 · $0.3557 M-Betahistine · DIN 02519690 · $0.3557 Mint-Betahistine · DIN 02538148 · $0.3557 NRA-Betahistine · DIN 02544938 · $0.3557 PMS-Betahistine · DIN 02330210 · $0.3557 Serc · DIN 02243878 · not recorded Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449153
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Betahistine · DIN 02519690 · 16mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Betahistine · DIN 02519690 Manufacturer: Mantra Pharma Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-07-25 · brand M-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Betahistine: Formulary list price $0.3557/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3557 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100893 · Verify on the e-Formulary ↗ (DIN 02519690)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02519690). DIN 02519690: M-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id MAT Source form: Tab; strength: 16mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.3557; ministry $0.3557 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519690 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100893
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557 Betahistine · DIN 02466449 · $0.3557 Co Betahistine · DIN 02374757 · $0.3557 Mint-Betahistine · DIN 02538148 · $0.3557 NRA-Betahistine · DIN 02544938 · $0.3557 PMS-Betahistine · DIN 02330210 · $0.3557 Serc · DIN 02243878 · not recorded Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: resolved shortage (ended 2025-02-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519690
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Betahistine · DIN 02538148 · 16mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Betahistine · DIN 02538148 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-01-31 Health Canada: Marketed since 2023-10-20 · brand MINT-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Betahistine: Formulary list price $0.3557/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3557 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102688 · Verify on the e-Formulary ↗ (DIN 02538148)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02538148). DIN 02538148: Mint-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id MIN Source form: Tab; strength: 16mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.3557; ministry $0.3557 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538148 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102688
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557 Betahistine · DIN 02466449 · $0.3557 Co Betahistine · DIN 02374757 · $0.3557 M-Betahistine · DIN 02519690 · $0.3557 NRA-Betahistine · DIN 02544938 · $0.3557 PMS-Betahistine · DIN 02330210 · $0.3557 Serc · DIN 02243878 · not recorded Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: resolved shortage (ended 2025-06-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538148
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Betahistine · DIN 02544938 · 16mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
NRA-Betahistine · DIN 02544938 Manufacturer: Nora Pharma; listing date 2024-08-30 Health Canada: Marketed since 2024-06-05 · brand NRA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Betahistine: Formulary list price $0.3557/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3557 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103355 · Verify on the e-Formulary ↗ (DIN 02544938)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02544938). DIN 02544938: NRA-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id NRA Source form: Tab; strength: 16mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.3557; ministry $0.3557 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544938 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103355
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557 Betahistine · DIN 02466449 · $0.3557 Co Betahistine · DIN 02374757 · $0.3557 M-Betahistine · DIN 02519690 · $0.3557 Mint-Betahistine · DIN 02538148 · $0.3557 PMS-Betahistine · DIN 02330210 · $0.3557 Serc · DIN 02243878 · not recorded Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: resolved shortage (ended 2025-02-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544938
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Serc · DIN 02243878 · 16mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Serc (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Serc · DIN 02243878 Manufacturer: BGP Pharma ULC; listing date 2007-09-04 Health Canada: Marketed since 2016-09-07 · brand SERC · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Serc: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67819 · Verify on the e-Formulary ↗ (DIN 02243878)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02243878). DIN 02243878: Serc Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id BGP Source form: Tab; strength: 16mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243878 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67819
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557 Betahistine · DIN 02466449 · $0.3557 Co Betahistine · DIN 02374757 · $0.3557 M-Betahistine · DIN 02519690 · $0.3557 Mint-Betahistine · DIN 02538148 · $0.3557 NRA-Betahistine · DIN 02544938 · $0.3557 PMS-Betahistine · DIN 02330210 · $0.3557 Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243878
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Betahistine · DIN 02280191 · 16mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Betahistine · DIN 02280191 Manufacturer: Teva Canada Limited; listing date 2007-09-04 Health Canada: Marketed since 2014-01-09 · brand TEVA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Betahistine: Formulary list price $0.3557/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3557 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76587 · Verify on the e-Formulary ↗ (DIN 02280191)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02280191). DIN 02280191: Teva-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id TEV Source form: Tab; strength: 16mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.3557; ministry $0.3557 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02280191 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76587
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557 Betahistine · DIN 02466449 · $0.3557 Co Betahistine · DIN 02374757 · $0.3557 M-Betahistine · DIN 02519690 · $0.3557 Mint-Betahistine · DIN 02538148 · $0.3557 NRA-Betahistine · DIN 02544938 · $0.3557 PMS-Betahistine · DIN 02330210 · $0.3557 Serc · DIN 02243878 · not recorded
Shortage status: discontinued (2025-08-28, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02280191
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Betahistine · DIN 02449161 · 24mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Betahistine · DIN 02449161 Manufacturer: Auro Pharma Inc.; listing date 2016-02-25 Health Canada: Marketed since 2015-11-30 · brand AURO-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93498 · Verify on the e-Formulary ↗ (DIN 02449161)

Source record
DIN 02449161: Auro-Betahistine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id AUR Source form: Tab; strength: 24mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4983; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02449161 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93498
Interchangeable products
Betahistine · DIN 02466457 · not recorded Co Betahistine · DIN 02374765 · not recorded M-Betahistine · DIN 02519704 · not recorded Mint-Betahistine · DIN 02538156 · not recorded NRA-Betahistine · DIN 02544946 · not recorded PMS-Betahistine · DIN 02330237 · not recorded Serc · DIN 02247998 · not recorded Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: resolved shortage (ended 2025-05-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02449161
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Betahistine · DIN 02519704 · 24mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Betahistine · DIN 02519704 Manufacturer: Mantra Pharma Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-07-25 · brand M-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100894 · Verify on the e-Formulary ↗ (DIN 02519704)

Source record
DIN 02519704: M-Betahistine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id MAT Source form: Tab; strength: 24mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4983; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519704 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100894
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded Betahistine · DIN 02466457 · not recorded Co Betahistine · DIN 02374765 · not recorded Mint-Betahistine · DIN 02538156 · not recorded NRA-Betahistine · DIN 02544946 · not recorded PMS-Betahistine · DIN 02330237 · not recorded Serc · DIN 02247998 · not recorded Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: resolved shortage (ended 2025-02-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519704
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Betahistine · DIN 02538156 · 24mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Betahistine · DIN 02538156 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-01-31 Health Canada: Marketed since 2023-10-31 · brand MINT-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102689 · Verify on the e-Formulary ↗ (DIN 02538156)

Source record
DIN 02538156: Mint-Betahistine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id MIN Source form: Tab; strength: 24mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4983; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538156 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102689
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded Betahistine · DIN 02466457 · not recorded Co Betahistine · DIN 02374765 · not recorded M-Betahistine · DIN 02519704 · not recorded NRA-Betahistine · DIN 02544946 · not recorded PMS-Betahistine · DIN 02330237 · not recorded Serc · DIN 02247998 · not recorded Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: resolved shortage (ended 2025-06-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538156
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Betahistine · DIN 02544946 · 24mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
NRA-Betahistine · DIN 02544946 Manufacturer: Nora Pharma; listing date 2024-08-30 Health Canada: Marketed since 2024-06-05 · brand NRA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103356 · Verify on the e-Formulary ↗ (DIN 02544946)

Source record
DIN 02544946: NRA-Betahistine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id NRA Source form: Tab; strength: 24mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4983; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544946 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103356
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded Betahistine · DIN 02466457 · not recorded Co Betahistine · DIN 02374765 · not recorded M-Betahistine · DIN 02519704 · not recorded Mint-Betahistine · DIN 02538156 · not recorded PMS-Betahistine · DIN 02330237 · not recorded Serc · DIN 02247998 · not recorded Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: resolved shortage (ended 2025-03-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544946
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Serc · DIN 02247998 · 24mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Serc (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Serc · DIN 02247998 Manufacturer: BGP Pharma ULC; listing date 2007-09-04 Health Canada: Marketed since 2016-06-20 · brand SERC · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Serc: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72312 · Verify on the e-Formulary ↗ (DIN 02247998)

Source record
DIN 02247998: Serc Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id BGP Source form: Tab; strength: 24mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247998 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72312
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded Betahistine · DIN 02466457 · not recorded Co Betahistine · DIN 02374765 · not recorded M-Betahistine · DIN 02519704 · not recorded Mint-Betahistine · DIN 02538156 · not recorded NRA-Betahistine · DIN 02544946 · not recorded PMS-Betahistine · DIN 02330237 · not recorded Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: resolved shortage (ended 2025-04-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247998
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Betahistine · DIN 02280205 · 24mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Betahistine · DIN 02280205 Manufacturer: Teva Canada Limited; listing date 2007-09-04 Health Canada: Marketed since 2014-01-09 · brand TEVA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76588 · Verify on the e-Formulary ↗ (DIN 02280205)

Source record
DIN 02280205: Teva-Betahistine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id TEV Source form: Tab; strength: 24mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4983; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02280205 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76588
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded Betahistine · DIN 02466457 · not recorded Co Betahistine · DIN 02374765 · not recorded M-Betahistine · DIN 02519704 · not recorded Mint-Betahistine · DIN 02538156 · not recorded NRA-Betahistine · DIN 02544946 · not recorded PMS-Betahistine · DIN 02330237 · not recorded Serc · DIN 02247998 · not recorded
Shortage status: discontinued (2025-08-28, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02280205
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Betahistine · DIN 02466449 · 16mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2026-07-23 · checked 2026-09-02 · What does dormant mean?
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Betahistine · DIN 02466449 Manufacturer: Sanis Health Inc.; listing date 2020-06-30 Health Canada: Dormant since 2026-07-23 · brand BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Betahistine: Formulary list price $0.3557/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3557 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95480 · Verify on the e-Formulary ↗ (DIN 02466449)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02466449). DIN 02466449: Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id SAI Source form: Tab; strength: 16mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.3557; ministry $0.3557 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466449 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95480
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557 Co Betahistine · DIN 02374757 · $0.3557 M-Betahistine · DIN 02519690 · $0.3557 Mint-Betahistine · DIN 02538148 · $0.3557 NRA-Betahistine · DIN 02544938 · $0.3557 PMS-Betahistine · DIN 02330210 · $0.3557 Serc · DIN 02243878 · not recorded Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: active shortage (reported 2024-11-05, last updated 2024-11-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02466449
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-23 — choose a marketed DIN from the same-category list.

PMS-Betahistine · DIN 02330210 · 16mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2025-07-31 · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Betahistine · DIN 02330210 Manufacturer: Pharmascience Inc.; listing date 2014-04-30 Health Canada: Dormant since 2025-07-31 · brand PMS-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Betahistine: Formulary list price $0.3557/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3557 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81597 · Verify on the e-Formulary ↗ (DIN 02330210)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02330210). DIN 02330210: PMS-Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id PMS Source form: Tab; strength: 16mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.3557; ministry $0.3557 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02330210 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81597
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557 Betahistine · DIN 02466449 · $0.3557 Co Betahistine · DIN 02374757 · $0.3557 M-Betahistine · DIN 02519690 · $0.3557 Mint-Betahistine · DIN 02538148 · $0.3557 NRA-Betahistine · DIN 02544938 · $0.3557 Serc · DIN 02243878 · not recorded Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: active shortage (reported not recorded, estimated to end 2027-01-01, last updated 2025-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330210
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-31 — choose a marketed DIN from the same-category list.

Betahistine · DIN 02466457 · 24mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2026-07-23 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Betahistine · DIN 02466457 Manufacturer: Sanis Health Inc.; listing date 2020-06-30 Health Canada: Dormant since 2026-07-23 · brand BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95481 · Verify on the e-Formulary ↗ (DIN 02466457)

Source record
DIN 02466457: Betahistine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id SAI Source form: Tab; strength: 24mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4983; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466457 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95481
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded Co Betahistine · DIN 02374765 · not recorded M-Betahistine · DIN 02519704 · not recorded Mint-Betahistine · DIN 02538156 · not recorded NRA-Betahistine · DIN 02544946 · not recorded PMS-Betahistine · DIN 02330237 · not recorded Serc · DIN 02247998 · not recorded Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: active shortage (reported 2024-12-03, last updated 2024-12-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02466457
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-23 — choose a marketed DIN from the same-category list.

PMS-Betahistine · DIN 02330237 · 24mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2025-07-31 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Betahistine · DIN 02330237 Manufacturer: Pharmascience Inc.; listing date 2014-04-30 Health Canada: Dormant since 2025-07-31 · brand PMS-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81599 · Verify on the e-Formulary ↗ (DIN 02330237)

Source record
DIN 02330237: PMS-Betahistine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id PMS Source form: Tab; strength: 24mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4983; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02330237 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81599
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded Betahistine · DIN 02466457 · not recorded Co Betahistine · DIN 02374765 · not recorded M-Betahistine · DIN 02519704 · not recorded Mint-Betahistine · DIN 02538156 · not recorded NRA-Betahistine · DIN 02544946 · not recorded Serc · DIN 02247998 · not recorded Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: active shortage (reported not recorded, estimated to end 2027-01-01, last updated 2025-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330237
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-31 — choose a marketed DIN from the same-category list.

Serc · DIN 02240601 · 8mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2005-02-07 — choose a marketed DIN from the same-category list.Discontinued 2005-02-07 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2005-02-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-02-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
Savings card: RxHelp ONE lists Serc (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Serc · DIN 02240601 Manufacturer: Solvay Pharma Inc.; listing date 2011-05-19 Health Canada: Cancelled post market since 2005-02-07 · brand SERC 8 MG · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG/TAB · company Solvay pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Serc: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64172 · Verify on the e-Formulary ↗ (DIN 02240601)

Source record
DIN 02240601: Serc Raw flags: sec3=Y, sec3b=Y Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id SPH Source form: Tab; strength: 8mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240601 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64172
Interchangeable products
Auro-Betahistine · DIN 02449145 · $0.2070 M-Betahistine · DIN 02519682 · $0.2259 Mint-Betahistine · DIN 02538121 · $0.2259 NRA-Betahistine · DIN 02544911 · $0.2259 Teva-Betahistine · DIN 02280183 · $0.2259
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240601
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2005-02-07 — choose a marketed DIN from the same-category list.

Co Betahistine · DIN 02374757 · 16mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.Discontinued 2018-06-12 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Co Betahistine · DIN 02374757 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-01-19 Health Canada: Cancelled post market since 2018-06-12 · brand ACT BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Actavis pharma company · schedule Prescription
Check this DIN again · Health Canada product record

Co Betahistine: Formulary list price $0.3557/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3557 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86007 · Verify on the e-Formulary ↗ (DIN 02374757)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02374757). DIN 02374757: Co Betahistine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id COB Source form: Tab; strength: 16mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.3557; ministry $0.3557 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02374757 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86007
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557 Betahistine · DIN 02466449 · $0.3557 M-Betahistine · DIN 02519690 · $0.3557 Mint-Betahistine · DIN 02538148 · $0.3557 NRA-Betahistine · DIN 02544938 · $0.3557 PMS-Betahistine · DIN 02330210 · $0.3557 Serc · DIN 02243878 · not recorded Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02374757
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.

Co Betahistine · DIN 02374765 · 24mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.Discontinued 2018-06-12 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Co Betahistine · DIN 02374765 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-01-19 Health Canada: Cancelled post market since 2018-06-12 · brand ACT BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Actavis pharma company · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86008 · Verify on the e-Formulary ↗ (DIN 02374765)

Source record
DIN 02374765: Co Betahistine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id COB Source form: Tab; strength: 24mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4983; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02374765 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86008
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded Betahistine · DIN 02466457 · not recorded M-Betahistine · DIN 02519704 · not recorded Mint-Betahistine · DIN 02538156 · not recorded NRA-Betahistine · DIN 02544946 · not recorded PMS-Betahistine · DIN 02330237 · not recorded Serc · DIN 02247998 · not recorded Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02374765
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:12 Vasodilating Drugs) and how they are covered

Matched class: 24:12 Vasodilating Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ISOSORBIDE DINITRATE, NITROGLYCERIN 24:12 Vasodilating Drugs

ISOSORBIDE DINITRATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 5mg, 10mg, 30mg · SL Tab, Tab

NITROGLYCERIN

· 20 products · General benefit (13), Temporary benefit (2), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 0.4mg/Hr/20 Sq Cm, 0.6mg/Hr/30 Sq Cm, 0.4mg/Hr/14 Sq Cm, 0.6mg/Hr/21 Sq Cm, 0.3mg, 0.6mg, 0.4mg/Metered Dose, 0.2mg/Hr, 0.4mg/Hr, 0.6mg/Hr, 0.8mg/Hr · Patch, SL Tab, Sp-180 Dose Pk, Sp-75 Dose Pk, Spray-200 Dose Pk, Transdermal Patch

DIPYRIDAMOLE & ACETYLSALICYLIC ACID

· 2 products · Listed, not a benefit (1), Limited Use, codes 349 (1) · strengths: 200mg/25mg · Cap

NIMODIPINE

· 1 products · Limited Use, codes 42, 43 · strengths: 30mg · Tab

VERICIGUAT

· 3 products · Limited Use, codes 685 · strengths: 2.5mg, 5mg, 10mg · Tab

AMBRISENTAN

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Tab

BOSENTAN MONOHYDRATE

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 62.5mg, 125mg · Tab

DIPYRIDAMOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 25mg, 50mg, 75mg · Tab

ISOSORBIDE-5-MONONITRATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 60mg · ER Tab

RIOCIGUAT

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5mg, 1.5mg, 1mg, 2.5mg, 2mg · Tab

TADALAFIL

· 73 products · Off-Formulary Interchangeable, not an ODB benefit (72), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

VARDENAFIL HCL

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 5mg, 20mg · Orally Disintergrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:12
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications SERC (betahistine dihydrochloride tablets) is indicated for: • Reducing the episodes of recurrent vertigo associated with Ménière’s disease. 1.1. Pediatrics Pediatrics (< 18 years of age): SERC is not recommended for use in children below 18 years of age due to insufficient data on safety and efficacy (see 7 Warnings and Precautions, Special populations, Pediatrics). 1.2. Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see 7 Warnings and Precautions, Special populations, Geriatrics). https://pdf.hres.ca/dpd_pm/00083994.PDF PM date: 2026-03-25 Source product: SERC; DIN 02243878; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Betahistine · DIN 02280183 Shortage status: discontinued (2025-08-28, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02280183

Check this DIN again

Teva-Betahistine · DIN 02280191 Shortage status: discontinued (2025-08-28, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02280191

Check this DIN again

Teva-Betahistine · DIN 02280205 Shortage status: discontinued (2025-08-28, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02280205

Check this DIN again

Betahistine · DIN 02466449 Shortage status: active shortage (reported 2024-11-05, last updated 2024-11-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02466449

Check this DIN again

PMS-Betahistine · DIN 02330210 Shortage status: active shortage (reported not recorded, estimated to end 2027-01-01, last updated 2025-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330210

Check this DIN again

Betahistine · DIN 02466457 Shortage status: active shortage (reported 2024-12-03, last updated 2024-12-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02466457

Check this DIN again

PMS-Betahistine · DIN 02330237 Shortage status: active shortage (reported not recorded, estimated to end 2027-01-01, last updated 2025-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330237

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Auro-Betahistine, M-Betahistine, Mint-Betahistine, NRA-Betahistine, Teva-Betahistine, Serc, Betahistine, PMS-Betahistine, Co Betahistine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026